DF/HCC Kidney Cancer SPORE

DF/HCC 肾癌孢子

• 批准号: 7910615
• 负责人: Michael Benjamin Atkins
• 金额: $ 230万
• 依托单位: BETH ISRAEL DEACONESS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-09-18 至 2014-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7910615
• 关键词: DF; HCC; Kidney; Cancer; SPORE

This application represents the renewal of the Specialized Program of Research Excellence in Kidney Cancer originating from the Kidney Cancer Program of the Dana-Farber Harvard Cancer Center (DF/HCC) and the Beth Israel Deaconess Medical Center. The DF/HCC Kidney Cancer SPORE includes investigators from all the Harvard affiliated hospitals - the Beth Israel Deaconess Medical Center, the Dana-Farber Cancer Institute, the Massachusetts General Hospital, the Brigham and Women's Hospital, and the Children's Hospital Medical Center, as well as the Harvard School of Public Health. Five major projects are supported through this application including: 1) Clinical Correlations of WTX Inactivation in Wilms Tumor; 2) Validation of RCC biomarkers for early disease detection and response to targeted therapy; 3) Acquired Resistance to VEGF Receptor Blockade: Underlying Mechanism and Therapeutic Options; 4), Targeting the PI3-Kinase/Akt Pathway in RCC: Mechanism of Action and Opportunities for Rational Combination Therapy; and 5) Adoptive Immunotherapy for Renal Carcinoma Using Dendritic Cell/tumor Fusions. These projects are integrated by three cores. These are: 1) Administration, Evaluation and Planning; 2) Biostatistics; and 3) Tissue Acquisition, Pathology and Clinical Data, This SPORE application outlines a Development Research Program which includes a plan for selection and review of new projects and examples of 4 recently funded and 3 projects that could be considered for future support. We also include a Career Development Program which outlines a mechanism for the identification, support, and review of talented young investigators in renal cancer. The overall goal of the DF/HCC Kidney Cancer SPORE is the translation of biological and technological advances into clinically meaningful advances for patients with kidney cancer.

本申请代表了来自Dana-Farber哈佛癌症中心（DF/HCC）和贝斯以色列女执事医疗中心肾癌项目的肾癌卓越研究专业项目的更新。DF/HCC肾癌孢子包括来自所有哈佛附属医院的研究人员-贝丝以色列女执事医疗中心，达纳法伯癌症研究所，马萨诸塞州总医院，布里格姆妇女医院和儿童医院医疗中心，以及哈佛公共卫生学院。通过该申请支持五个主要项目，包括：1）肾母细胞瘤中WTX失活的临床相关性; 2）用于早期疾病检测和靶向治疗反应的RCC生物标志物的验证; 3）获得性VEGF受体阻断剂耐药：潜在机制和治疗选择; 4）靶向RCC中的PI 3-激酶/Akt通路：合理联合治疗的作用机制和机会; 5）树突状细胞/肿瘤融合体的免疫治疗。这些项目由三个核心组成。这些措施包括：1）管理、评估和规划; 2）生物统计学;以及3）组织采集、病理学和临床数据。此SPORE应用程序概述了开发研究计划，其中包括新项目的选择和审查计划以及4个最近资助的项目和3个可考虑用于未来支持的项目的示例。我们还包括一个职业发展计划，概述了一个机制，用于识别，支持和审查有才华的年轻肾癌研究人员。DF/HCC肾癌SPORE的总体目标是将生物和技术进步转化为对肾癌患者有临床意义的进步。